Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urogenital Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Prostatic Diseases 1Neoplasms by Site 1Neoplasms 1Genital Neoplasms, Male 1Genital Diseases, Male 1

Interventions

Nivolumab 2Ipilimumab 2vedolizumab 1gallium 68 PSMA-11 1fludarabine 1cabozantinib 1aldesleukin 1abiraterone 1abemaciclib 1Therapeutics 1Specimen Handling 1Prednisone 1Prednisolone 1Magnetic Resonance Spectroscopy 1LDP-02 1Interleukin-2 1Infliximab 1Immunoglobulin G 1Geriatric Assessment 1Fulvestrant 1Exercise 1Disulfides 1Cyclophosphamide 1CTLA-4 Antigen 1CT-P13 1Biopsy 1Androgen Antagonists 1Adrenal Cortex Hormones 1(225)Ac-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Urogenital Neoplasms × (225)Ac-PSMA-617 × Clear all
NCT04597411 2026-04-30

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer

Endocyte

Phase 1 Active not recruiting
101 enrolled
Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡